{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013056",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013056_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"acalabrutinib\" outputclass=\"int-drug\">Acalabrutinib</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Acalabrutinib   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acalabrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013057",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013057_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">Aceclofenac</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Aceclofenac   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aceclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013058",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013058_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"acenocoumarol\" outputclass=\"int-drug\">Acenocoumarol</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Acenocoumarol   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acenocoumarol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013059",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013059_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"adalimumab\" outputclass=\"int-drug\">adalimumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  adalimumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Adalimumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013060",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013060_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"aldesleukin\" outputclass=\"int-drug\">aldesleukin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  aldesleukin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aldesleukin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013061",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013061_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"alemtuzumab\" outputclass=\"int-drug\">alemtuzumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  alemtuzumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alemtuzumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013062",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013062_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"alprostadil\" outputclass=\"int-drug\">Alprostadil</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Alprostadil   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alprostadil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013063",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013063_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"alteplase\" outputclass=\"int-drug\">Alteplase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Alteplase   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013064",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013064_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"amsacrine\" outputclass=\"int-drug\">amsacrine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  amsacrine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amsacrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013065",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013065_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">Anagrelide</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Anagrelide   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anagrelide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013066",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013066_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"apalutamide\" outputclass=\"int-drug\">Apalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Apalutamide   is predicted to   decrease   the exposure to   ruxolitinib .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013067",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013067_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"apixaban\" outputclass=\"int-drug\">Apixaban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Apixaban   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apixaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013068",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013068_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"aprepitant\" outputclass=\"int-drug\">Aprepitant</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Aprepitant   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aprepitant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013069",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013069_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"argatroban\" outputclass=\"int-drug\">Argatroban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Argatroban   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Argatroban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013070",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013070_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"arsenic trioxide\" outputclass=\"int-drug\">arsenic trioxide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  arsenic trioxide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Arsenic trioxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013071",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013071_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"asparaginase\" outputclass=\"int-drug\">asparaginase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  asparaginase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Asparaginase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013072",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013072_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"aspirin\" outputclass=\"int-drug\">Aspirin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Aspirin   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aspirin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013073",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013073_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"atazanavir\" outputclass=\"int-drug\">Atazanavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Atazanavir   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises adjust dose and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atazanavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013074",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013074_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"axitinib\" outputclass=\"int-drug\">axitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  axitinib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013074_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"axitinib\" outputclass=\"int-drug\">Axitinib</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Axitinib   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Axitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013075",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013075_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"azacitidine\" outputclass=\"int-drug\">azacitidine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  azacitidine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azacitidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013076",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013076_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"azathioprine\" outputclass=\"int-drug\">azathioprine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  azathioprine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azathioprine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013077",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013077_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"belatacept\" outputclass=\"int-drug\">belatacept</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  belatacept  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Belatacept</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013078",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013078_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bemiparin\" outputclass=\"int-drug\">Bemiparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bemiparin   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bemiparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013079",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013079_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"bendamustine\" outputclass=\"int-drug\">bendamustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  bendamustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendamustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013080",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013080_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"benzydamine\" outputclass=\"int-drug\">Benzydamine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Benzydamine   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Benzydamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013081",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013081_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"bevacizumab\" outputclass=\"int-drug\">bevacizumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  bevacizumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bevacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013082",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013082_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"bexarotene\" outputclass=\"int-drug\">bexarotene</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  bexarotene  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bexarotene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013083",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013083_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bivalirudin\" outputclass=\"int-drug\">Bivalirudin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bivalirudin   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bivalirudin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013084",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013084_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"bleomycin\" outputclass=\"int-drug\">bleomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  bleomycin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bleomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013085",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013085_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"blinatumomab\" outputclass=\"int-drug\">blinatumomab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  blinatumomab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Blinatumomab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013086",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013086_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"bortezomib\" outputclass=\"int-drug\">bortezomib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  bortezomib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bortezomib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013087",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013087_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"bosentan\" outputclass=\"int-drug\">Bosentan</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Bosentan   is predicted to   decrease   the exposure to   ruxolitinib .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosentan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013088",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013088_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  bosutinib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013088_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">Bosutinib</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Bosutinib   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013089",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013089_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-drug\">brentuximab vedotin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  brentuximab vedotin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Brentuximab vedotin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013090",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013090_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bromfenac\" outputclass=\"int-drug\">Bromfenac</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bromfenac   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bromfenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013091",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013091_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"busulfan\" outputclass=\"int-drug\">busulfan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  busulfan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Busulfan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013092",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013092_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"cabazitaxel\" outputclass=\"int-drug\">cabazitaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  cabazitaxel  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabazitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013093",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013093_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  cabozantinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013094",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013094_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"canakinumab\" outputclass=\"int-drug\">canakinumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  canakinumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Canakinumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013095",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013095_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"cangrelor\" outputclass=\"int-drug\">Cangrelor</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Cangrelor   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cangrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013096",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013096_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"capecitabine\" outputclass=\"int-drug\">capecitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  capecitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Capecitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013097",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013097_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   decrease   the exposure to   ruxolitinib .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013098",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013098_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"carboplatin\" outputclass=\"int-drug\">carboplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  carboplatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carboplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013099",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013099_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"carfilzomib\" outputclass=\"int-drug\">carfilzomib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  carfilzomib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carfilzomib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013100",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013100_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"carmustine\" outputclass=\"int-drug\">carmustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  carmustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carmustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013101",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013101_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013102",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013102_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"ceritinib\" outputclass=\"int-drug\">ceritinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  ceritinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceritinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013103",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013103_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"certolizumab pegol\" outputclass=\"int-drug\">certolizumab pegol</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  certolizumab pegol  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Certolizumab pegol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013104",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013104_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"chlorambucil\" outputclass=\"int-drug\">chlorambucil</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  chlorambucil  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorambucil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013105",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013105_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"cilostazol\" outputclass=\"int-drug\">Cilostazol</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Cilostazol   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cilostazol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013106",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013106_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"cisplatin\" outputclass=\"int-drug\">cisplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  cisplatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cisplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013107",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013107_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"citalopram\" outputclass=\"int-drug\">Citalopram</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Citalopram   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013108",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013108_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"cladribine\" outputclass=\"int-drug\">cladribine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  cladribine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cladribine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013109",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013109_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">Clarithromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Clarithromycin   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises adjust dose and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013110",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013110_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"clofarabine\" outputclass=\"int-drug\">clofarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  clofarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clofarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013111",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013111_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clopidogrel\" outputclass=\"int-drug\">Clopidogrel</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Clopidogrel   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clopidogrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013112",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013112_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"cobicistat\" outputclass=\"int-drug\">Cobicistat</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Cobicistat   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises adjust dose and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobicistat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013113",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013113_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"crisantaspase\" outputclass=\"int-drug\">crisantaspase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  crisantaspase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crisantaspase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013114",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013114_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"crizotinib\" outputclass=\"int-drug\">Crizotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Crizotinib   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crizotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013115",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013115_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"cyclophosphamide\" outputclass=\"int-drug\">cyclophosphamide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  cyclophosphamide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyclophosphamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013116",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013116_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"cytarabine\" outputclass=\"int-drug\">cytarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  cytarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cytarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013117",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013117_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dabigatran\" outputclass=\"int-drug\">Dabigatran</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dabigatran   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabigatran</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013118",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013118_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dabrafenib\" outputclass=\"int-drug\">Dabrafenib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dabrafenib   is predicted to   decrease   the exposure to   ruxolitinib .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabrafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013119",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013119_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"dacarbazine\" outputclass=\"int-drug\">dacarbazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  dacarbazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dacarbazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013120",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013120_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"dactinomycin\" outputclass=\"int-drug\">dactinomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  dactinomycin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dactinomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013121",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013121_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dalteparin\" outputclass=\"int-drug\">Dalteparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dalteparin   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dalteparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013122",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013122_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"danaparoid\" outputclass=\"int-drug\">Danaparoid</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Danaparoid   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Danaparoid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013123",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013123_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">Dapoxetine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dapoxetine   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013124",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013124_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"daratumumab\" outputclass=\"int-drug\">daratumumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  daratumumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Daratumumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013125",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013125_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"darunavir\" outputclass=\"int-drug\">Darunavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Darunavir   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises adjust dose and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darunavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013126",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013126_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  dasatinib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013126_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">Dasatinib</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dasatinib   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013127",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013127_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"daunorubicin\" outputclass=\"int-drug\">daunorubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  daunorubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Daunorubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013128",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013128_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"decitabine\" outputclass=\"int-drug\">decitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  decitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Decitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013129",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013129_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">Dexketoprofen</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dexketoprofen   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013130",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013130_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"dexrazoxane\" outputclass=\"int-drug\">dexrazoxane</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  dexrazoxane  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexrazoxane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013131",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013131_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">Diclofenac</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Diclofenac   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013132",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013132_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"diltiazem\" outputclass=\"int-drug\">Diltiazem</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Diltiazem   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diltiazem</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013133",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013133_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"dinutuximab\" outputclass=\"int-drug\">dinutuximab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  dinutuximab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dinutuximab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013134",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013134_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dipyridamole\" outputclass=\"int-drug\">Dipyridamole</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dipyridamole   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipyridamole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013135",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013135_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"docetaxel\" outputclass=\"int-drug\">docetaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  docetaxel  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Docetaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013136",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013136_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"doxorubicin\" outputclass=\"int-drug\">doxorubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  doxorubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxorubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013137",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013137_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronedarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013138",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013138_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">Duloxetine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Duloxetine   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Duloxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013139",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013139_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"edoxaban\" outputclass=\"int-drug\">Edoxaban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Edoxaban   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Edoxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013140",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013140_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"efavirenz\" outputclass=\"int-drug\">Efavirenz</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Efavirenz   is predicted to   decrease   the exposure to   ruxolitinib .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Efavirenz</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013141",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013141_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eicosapentaenoic acid\" outputclass=\"int-drug\">Eicosapentaenoic acid</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eicosapentaenoic acid   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eicosapentaenoic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013142",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013142_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enoxaparin\" outputclass=\"int-drug\">Enoxaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Enoxaparin   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enoxaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013143",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013143_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"enzalutamide\" outputclass=\"int-drug\">Enzalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Enzalutamide   is predicted to   decrease   the exposure to   ruxolitinib .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enzalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013144",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013144_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"epirubicin\" outputclass=\"int-drug\">epirubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  epirubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epirubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013145",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013145_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"epoprostenol\" outputclass=\"int-drug\">Epoprostenol</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Epoprostenol   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoprostenol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013146",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013146_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eptifibatide\" outputclass=\"int-drug\">Eptifibatide</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eptifibatide   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eptifibatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013147",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013147_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"eribulin\" outputclass=\"int-drug\">eribulin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  eribulin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eribulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013148",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013148_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"erythromycin\" outputclass=\"int-drug\">Erythromycin</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Erythromycin   slightly   increases   the exposure to   ruxolitinib .  Manufacturer advises monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erythromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013149",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013149_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">Escitalopram</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Escitalopram   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013150",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013150_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"estramustine\" outputclass=\"int-drug\">estramustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  estramustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Estramustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013151",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013151_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etodolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013152",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013152_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"etoposide\" outputclass=\"int-drug\">etoposide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  etoposide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoposide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013153",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013153_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">Etoricoxib</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etoricoxib   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoricoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013154",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013154_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">Fluconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluconazole   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013155",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013155_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"fludarabine\" outputclass=\"int-drug\">fludarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  fludarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013156",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013156_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"fluorouracil\" outputclass=\"int-drug\">fluorouracil</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  fluorouracil  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluorouracil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013157",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013157_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">Fluoxetine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluoxetine   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013158",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013158_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">Flurbiprofen</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Flurbiprofen   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flurbiprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013159",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013159_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvoxamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013160",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013160_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fondaparinux\" outputclass=\"int-drug\">Fondaparinux</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fondaparinux   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fondaparinux</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013161",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013161_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fosamprenavir\" outputclass=\"int-drug\">Fosamprenavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fosamprenavir   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises adjust dose and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosamprenavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013162",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013162_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">Fosphenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fosphenytoin   is predicted to   decrease   the exposure to   ruxolitinib .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013163",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013163_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"ganciclovir\" outputclass=\"int-drug\">ganciclovir</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  ganciclovir  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013164",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013164_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"gemcitabine\" outputclass=\"int-drug\">gemcitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  gemcitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gemcitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013165",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013165_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"gemtuzumab ozogamicin\" outputclass=\"int-drug\">gemtuzumab ozogamicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  gemtuzumab ozogamicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gemtuzumab ozogamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013166",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013166_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"golimumab\" outputclass=\"int-drug\">golimumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  golimumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Golimumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013167",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013167_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"grapefruit\" outputclass=\"int-drug\">Grapefruit</ph> <ph outputclass=\"int-substanceQualifier\">juice</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Grapefruit   juice   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Grapefruit</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013168",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013168_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"heparin\" outputclass=\"int-drug\">Heparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Heparin   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Heparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013169",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013169_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"hydroxycarbamide\" outputclass=\"int-drug\">hydroxycarbamide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  hydroxycarbamide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxycarbamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013170",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013170_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\">ibrutinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  ibrutinib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013170_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\">Ibrutinib</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Ibrutinib   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013171",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013171_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">Ibuprofen</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ibuprofen   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013172",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013172_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"idarubicin\" outputclass=\"int-drug\">idarubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  idarubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idarubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013173",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013173_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"idelalisib\" outputclass=\"int-drug\">Idelalisib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Idelalisib   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises adjust dose and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idelalisib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013174",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013174_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"ifosfamide\" outputclass=\"int-drug\">ifosfamide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  ifosfamide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ifosfamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013175",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013175_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"iloprost\" outputclass=\"int-drug\">Iloprost</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Iloprost   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iloprost</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013176",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013176_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"imatinib\" outputclass=\"int-drug\">imatinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  imatinib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013176_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"imatinib\" outputclass=\"int-drug\">Imatinib</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Imatinib   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013176_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"imatinib\" outputclass=\"int-drug\">Imatinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "3",
							"hasTextContent": "Imatinib   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013177",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013177_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indometacin\" outputclass=\"int-drug\">Indometacin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Indometacin   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indometacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013178",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013178_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"infliximab\" outputclass=\"int-drug\">infliximab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  infliximab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Infliximab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013179",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013179_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"inotuzumab ozogamicin\" outputclass=\"int-drug\">inotuzumab ozogamicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  inotuzumab ozogamicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotuzumab ozogamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013180",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013180_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"ipilimumab\" outputclass=\"int-drug\">ipilimumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  ipilimumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ipilimumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013181",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013181_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"irinotecan\" outputclass=\"int-drug\">irinotecan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  irinotecan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irinotecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013182",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013182_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"isavuconazole\" outputclass=\"int-drug\">Isavuconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Isavuconazole   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isavuconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013183",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013183_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"itraconazole\" outputclass=\"int-drug\">Itraconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Itraconazole   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises adjust dose and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Itraconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013184",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013184_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ketoconazole\" outputclass=\"int-drug\">Ketoconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ketoconazole   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises adjust dose and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013185",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013185_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">Ketoprofen</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ketoprofen   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013186",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013186_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">Ketorolac</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ketorolac   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketorolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013187",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013187_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"leflunomide\" outputclass=\"int-drug\">leflunomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  leflunomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Leflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013188",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013188_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"lenalidomide\" outputclass=\"int-drug\">lenalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  lenalidomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013189",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013189_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lenvatinib\" outputclass=\"int-drug\">Lenvatinib</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lenvatinib   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenvatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013190",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013190_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"letermovir\" outputclass=\"int-drug\">Letermovir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Letermovir   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Letermovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013191",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013191_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"lomustine\" outputclass=\"int-drug\">lomustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  lomustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lomustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013192",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013192_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"lopinavir\" outputclass=\"int-drug\">Lopinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Lopinavir   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises adjust dose and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lopinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013193",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013193_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">Mefenamic acid</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mefenamic acid   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013194",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013194_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">Meloxicam</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meloxicam   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meloxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013195",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013195_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"melphalan\" outputclass=\"int-drug\">melphalan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  melphalan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Melphalan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013196",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013196_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"mercaptopurine\" outputclass=\"int-drug\">mercaptopurine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  mercaptopurine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mercaptopurine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013197",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013197_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  methotrexate  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methotrexate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013198",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013198_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"mifamurtide\" outputclass=\"int-drug\">mifamurtide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  mifamurtide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mifamurtide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013199",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013199_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"mitomycin\" outputclass=\"int-drug\">mitomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  mitomycin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013200",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013200_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"mitotane\" outputclass=\"int-drug\">mitotane</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  mitotane  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013200_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"mitotane\" outputclass=\"int-drug\">Mitotane</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Mitotane   is predicted to   decrease   the exposure to   ruxolitinib .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitotane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013201",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013201_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"mitoxantrone\" outputclass=\"int-drug\">mitoxantrone</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  mitoxantrone  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitoxantrone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013202",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013202_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"mogamulizumab\" outputclass=\"int-drug\">mogamulizumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  mogamulizumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mogamulizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013203",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013203_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">Nabumetone</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nabumetone   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nabumetone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013204",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013204_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"naproxen\" outputclass=\"int-drug\">Naproxen</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Naproxen   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naproxen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013205",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013205_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"nelarabine\" outputclass=\"int-drug\">nelarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  nelarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nelarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013206",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013206_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"netupitant\" outputclass=\"int-drug\">Netupitant</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Netupitant   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Netupitant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013207",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013207_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"nevirapine\" outputclass=\"int-drug\">Nevirapine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Nevirapine   is predicted to   decrease   the exposure to   ruxolitinib .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nevirapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013208",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013208_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nicotinic acid\" outputclass=\"int-drug\">Nicotinic acid</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nicotinic acid   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicotinic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013209",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013209_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">nilotinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  nilotinib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013209_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">Nilotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Nilotinib   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013210",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013210_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nintedanib\" outputclass=\"int-drug\">Nintedanib</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nintedanib   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nintedanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013211",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013211_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"niraparib\" outputclass=\"int-drug\">niraparib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  niraparib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Niraparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013212",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013212_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"nivolumab\" outputclass=\"int-drug\">nivolumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  nivolumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nivolumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013213",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013213_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"obinutuzumab\" outputclass=\"int-drug\">obinutuzumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  obinutuzumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Obinutuzumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013214",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013214_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"olaparib\" outputclass=\"int-drug\">olaparib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  olaparib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olaparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013215",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013215_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"omega-3-acid ethyl esters\" outputclass=\"int-drug\">Omega-3-acid ethyl esters</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Omega-3-acid ethyl esters   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Omega-3-acid ethyl esters</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013216",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013216_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"oxaliplatin\" outputclass=\"int-drug\">oxaliplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  oxaliplatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxaliplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013217",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013217_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"paclitaxel\" outputclass=\"int-drug\">paclitaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  paclitaxel  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paclitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013218",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013218_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"palbociclib\" outputclass=\"int-drug\">palbociclib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  palbociclib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Palbociclib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013219",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013219_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"panobinostat\" outputclass=\"int-drug\">panobinostat</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  panobinostat  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Panobinostat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013220",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013220_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">Parecoxib</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Parecoxib   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Parecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013221",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013221_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">Paroxetine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Paroxetine   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013222",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013222_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">Pazopanib</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Pazopanib   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013223",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013223_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"pegaspargase\" outputclass=\"int-drug\">pegaspargase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  pegaspargase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pegaspargase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013224",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013224_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"peginterferon alfa\" outputclass=\"int-drug\">peginterferon alfa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  peginterferon alfa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Peginterferon alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013225",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013225_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"pembrolizumab\" outputclass=\"int-drug\">pembrolizumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  pembrolizumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pembrolizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013226",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013226_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"pemetrexed\" outputclass=\"int-drug\">pemetrexed</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  pemetrexed  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pemetrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013227",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013227_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"pentostatin\" outputclass=\"int-drug\">pentostatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  pentostatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentostatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013228",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013228_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenazone\" outputclass=\"int-drug\">Phenazone</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenazone   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013229",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013229_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenindione\" outputclass=\"int-drug\">Phenindione</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenindione   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenindione</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013230",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013230_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   decrease   the exposure to   ruxolitinib .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "175",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013231",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013231_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">Phenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Phenytoin   is predicted to   decrease   the exposure to   ruxolitinib .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "176",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013232",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013232_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">Piroxicam</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Piroxicam   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "177",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Piroxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013233",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013233_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"pixantrone\" outputclass=\"int-drug\">pixantrone</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  pixantrone  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "178",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pixantrone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013234",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013234_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"pomalidomide\" outputclass=\"int-drug\">pomalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  pomalidomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "179",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pomalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013235",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013235_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ponatinib\" outputclass=\"int-drug\">Ponatinib</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ponatinib   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "180",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ponatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013236",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013236_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"posaconazole\" outputclass=\"int-drug\">Posaconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Posaconazole   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "181",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Posaconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013237",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013237_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"prasugrel\" outputclass=\"int-drug\">Prasugrel</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Prasugrel   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "182",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prasugrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013238",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013238_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   decrease   the exposure to   ruxolitinib .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "183",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013239",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013239_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"procarbazine\" outputclass=\"int-drug\">procarbazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  procarbazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "184",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Procarbazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013240",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013240_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"raltitrexed\" outputclass=\"int-drug\">raltitrexed</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  raltitrexed  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "185",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Raltitrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013241",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013241_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"ramucirumab\" outputclass=\"int-drug\">ramucirumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  ramucirumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "186",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ramucirumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013242",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013242_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">regorafenib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  regorafenib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013242_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">Regorafenib</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Regorafenib   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "187",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Regorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013243",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013243_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"ribociclib\" outputclass=\"int-drug\">ribociclib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  ribociclib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "188",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ribociclib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013244",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013244_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   is predicted to   decrease   the exposure to   ruxolitinib .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "189",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013245",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013245_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ritonavir\" outputclass=\"int-drug\">Ritonavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ritonavir   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises adjust dose and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "190",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ritonavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013246",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013246_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"rituximab\" outputclass=\"int-drug\">rituximab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  rituximab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "191",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rituximab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013247",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013247_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rivaroxaban\" outputclass=\"int-drug\">Rivaroxaban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rivaroxaban   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "192",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rivaroxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013248",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013248_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"ropeginterferon alfa\" outputclass=\"int-drug\">ropeginterferon alfa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  ropeginterferon alfa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "193",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ropeginterferon alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013249",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013249_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"rucaparib\" outputclass=\"int-drug\">rucaparib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  rucaparib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "194",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rucaparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013250",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013250_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"sertraline\" outputclass=\"int-drug\">Sertraline</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Sertraline   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "195",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sertraline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013251",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013251_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  sorafenib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013251_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">Sorafenib</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Sorafenib   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "196",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013252",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013252_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"St John's wort\" outputclass=\"int-drug\">St John's wort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "St John's wort   is predicted to   decrease   the exposure to   ruxolitinib .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "197",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013253",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013253_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"streptokinase\" outputclass=\"int-drug\">Streptokinase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Streptokinase   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "198",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013254",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013254_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"streptozocin\" outputclass=\"int-drug\">streptozocin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  streptozocin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "199",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptozocin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013255",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013255_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"sulfasalazine\" outputclass=\"int-drug\">sulfasalazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  sulfasalazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "200",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfasalazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013256",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013256_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"sulindac\" outputclass=\"int-drug\">Sulindac</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Sulindac   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "201",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulindac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013257",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013257_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  sunitinib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013257_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">Sunitinib</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Sunitinib   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "202",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013258",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013258_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"talazoparib\" outputclass=\"int-drug\">talazoparib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  talazoparib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "203",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Talazoparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013259",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013259_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"tegafur\" outputclass=\"int-drug\">tegafur</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  tegafur  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "204",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tegafur</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013260",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013260_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"temozolomide\" outputclass=\"int-drug\">temozolomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  temozolomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "205",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Temozolomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013261",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013261_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"temsirolimus\" outputclass=\"int-drug\">temsirolimus</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  temsirolimus  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "206",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Temsirolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013262",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013262_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tenecteplase\" outputclass=\"int-drug\">Tenecteplase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tenecteplase   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "207",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenecteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013263",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013263_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">Tenoxicam</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tenoxicam   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "208",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenoxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013264",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013264_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"thalidomide\" outputclass=\"int-drug\">thalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  thalidomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "209",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013265",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013265_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"thiotepa\" outputclass=\"int-drug\">thiotepa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  thiotepa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "210",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thiotepa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013266",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013266_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">Tiaprofenic acid</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tiaprofenic acid   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "211",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tiaprofenic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013267",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013267_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ticagrelor\" outputclass=\"int-drug\">Ticagrelor</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ticagrelor   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "212",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ticagrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013268",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013268_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "213",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tinzaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013269",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013269_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"tioguanine\" outputclass=\"int-drug\">tioguanine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  tioguanine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "214",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tioguanine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013270",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013270_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises adjust dose and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "215",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013271",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013271_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tirofiban\" outputclass=\"int-drug\">Tirofiban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tirofiban   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "216",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tirofiban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013272",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013272_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">Tolfenamic acid</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tolfenamic acid   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "217",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolfenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013273",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013273_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"topotecan\" outputclass=\"int-drug\">topotecan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  topotecan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "218",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Topotecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013274",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013274_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"trabectedin\" outputclass=\"int-drug\">trabectedin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  trabectedin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "219",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trabectedin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013275",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013275_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"trastuzumab\" outputclass=\"int-drug\">trastuzumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  trastuzumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "220",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trastuzumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013276",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013276_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"trastuzumab deruxtecan\" outputclass=\"int-drug\">trastuzumab deruxtecan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  trastuzumab deruxtecan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "221",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trastuzumab deruxtecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013277",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013277_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"trastuzumab emtansine\" outputclass=\"int-drug\">trastuzumab emtansine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  trastuzumab emtansine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "222",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trastuzumab emtansine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013278",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013278_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"treosulfan\" outputclass=\"int-drug\">treosulfan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  treosulfan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "223",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Treosulfan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013279",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013279_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"treprostinil\" outputclass=\"int-drug\">Treprostinil</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Treprostinil   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "224",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Treprostinil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013280",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013280_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"urokinase\" outputclass=\"int-drug\">Urokinase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Urokinase   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "225",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Urokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013281",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013281_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"valganciclovir\" outputclass=\"int-drug\">valganciclovir</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  valganciclovir  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "226",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013282",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013282_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">Venlafaxine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Venlafaxine   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "227",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013283",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013283_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"verapamil\" outputclass=\"int-drug\">Verapamil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Verapamil   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "228",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Verapamil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013284",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013284_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"vinblastine\" outputclass=\"int-drug\">vinblastine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  vinblastine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "229",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinblastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013285",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013285_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"vincristine\" outputclass=\"int-drug\">vincristine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  vincristine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "230",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vincristine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013286",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013286_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"vindesine\" outputclass=\"int-drug\">vindesine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  vindesine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "231",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vindesine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013287",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013287_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  vinflunine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "232",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinflunine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013288",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013288_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> and <ph otherprops=\"vinorelbine\" outputclass=\"int-drug\">vinorelbine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  ruxolitinib  and  vinorelbine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "233",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinorelbine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013289",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013289_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">Voriconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Voriconazole   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises adjust dose and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "234",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013290",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013290_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">Vortioxetine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Vortioxetine   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "235",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vortioxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013291",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2#bnf_i1643858013291_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"warfarin\" outputclass=\"int-drug\">Warfarin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-heading-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Warfarin   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "236",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				}
			],
			"hasSearchLabel": " Ruxolitinib  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/ruxolitinib-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Ruxolitinib </title>"
			},
			"rdfs:label": "ruxolitinib"
		}
	]
}